Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
CA: A Cancer Journal for Clinicians · 2023-09 · 73 (5) · 480-515
DOI: 10.3322/caac.21777 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 20.03.2023. Verfasst von Laura A Huppert und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 151-mal zitiert (Crossref) und nennt 234 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR‐positive/HER2‐negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late‐stage disease. Combinations with cyclin‐dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody‐drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR‐positive/HER2‐negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR‐positive/HER2‐negative breast cancer, including treatment algorithms based on current data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
- Department of Medical Oncology, Acibadem University, School of Medicine, Istanbul, Turkey.
- Masonic Comprehensive Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Laura A Huppert, Hope S Rugo
Zitieren
APA
Huppert, L. A., Gumusay, O., Idossa, D., & Rugo, H. S. (2023). Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer. CA: A Cancer Journal for Clinicians, 73(5), 480-515. https://doi.org/10.3322/caac.21777
Vancouver
Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer. CA: A Cancer Journal for Clinicians. 2023;73(5):480-515. doi:10.3322/caac.21777
BibTeX
@article{Huppert2023,
author = {Huppert, Laura A and Gumusay, Ozge and Idossa, Dame and Rugo, Hope S},
title = {Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer},
journal = {CA: A Cancer Journal for Clinicians},
year = {2023},
volume = {73},
number = {5},
pages = {480--515},
doi = {10.3322/caac.21777}
}
EUVIMED